Gembitskiĭ E V, Begunov A B
Klin Med (Mosk). 1994;72(2):30-2.
In the authors' study it is shown that the mechanism of cardiovascular complications arising in prostatic cancer (PC) patients on estrogen therapy works through developing defects in coagulation which result in hypercoagulation and deterioration of blood rheology due to enhanced platelet aggregation. Activation of fibrinolytic enzymes seems to be an adaptive reaction decreasing hypercoagulation. The authors believe it necessary to evaluate cardiovascular and coagulative systems of PC patients before estrogen therapy to define the risk of probable complications, to design adequate prophylaxis and treatment with coronary-active and antihypertensive drugs, heparin, acetylsalicylic acid which help to prevent relevant cardiovascular complications and improve outcomes of the disease.
作者的研究表明，接受雌激素治疗的前列腺癌（PC）患者出现心血管并发症的机制是通过凝血功能缺陷，导致高凝状态以及由于血小板聚集增强而使血液流变学恶化。纤维蛋白溶解酶的激活似乎是一种降低高凝状态的适应性反应。作者认为，在雌激素治疗前评估PC患者的心血管和凝血系统，以确定可能并发症的风险，设计使用冠状动脉活性药物、抗高血压药物、肝素、乙酰水杨酸进行适当的预防和治疗是必要的，这些药物有助于预防相关心血管并发症并改善疾病预后。
